Synapse - Carol Aghajanian

Results (615)

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer (HGOC)

Meeting Abstract

Coleman, R. L.; Oza, A.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J.; Clamp, A.; Scambia, G.; more...
International Journal of Gynecological Cancer (2021)

Fulltext@MSK | Save

Preexisting TP53-variant clonal hematopoiesis and risk of secondary myeloid neoplasms in patients with high-grade ovarian cancer treated with rucaparib

Journal Article

Kwan, T. T.; Oza, A. M.; Tinker, A. V.; Ray-Coquard, I.; Oaknin, A.; Aghajanian, C.; Lorusso, D.; Colombo, N.; Dean, A.; Weberpals, J.; more...
JAMA Oncology (2021)

Fulltext@MSK | Save

Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer

Journal Article

Swisher, E. M.; Kristeleit, R. S.; Oza, A. M.; Tinker, A. V.; Ray-Coquard, I.; Oaknin, A.; Coleman, R. L.; Burris, H. A.; Aghajanian, C.; O'Malley, D. M.; more...
Gynecologic Oncology (2021)

Fulltext@MSK | Save

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

Journal Article

Banerjee, S.; Moore, K. N.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; more...
Lancet Oncology (2021)

Fulltext@MSK | Save

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer (HGOC)

Meeting Abstract

Kwan, T.; Oza, A. M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A. P.; Colombo, N.; Weberpals, J. I.; Clamp, A. R.; Scambia, G.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC)

Meeting Abstract

Grisham, R. N.; Vergote, I.; Banerjee, S. N.; Drill, E. N.; Fabbro, M.; Mirza, M. R.; Romero, I.; Coleman, R. L.; Oza, A. M.; Hilpert, F.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study

Meeting Abstract

Mathews, C. A.; Simpkins, F.; Cadoo, K. A.; Liu, Y. L.; Provencher, D. M.; McCormick, C.; ElNaggar, A.; Altman, A. D.; Gilbert, L.; Black, D.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Disparities in pan-cancer patients undergoing germline cancer risk assessment by self-reported race/ethnicity and ancestry

Meeting Abstract

Liu, Y. L.; Maio, A.; Kemel, Y.; Salo-Mullen, E. E.; Sheehan, M.; Tejada, P. R.; Trottier, M.; Fleischut, M. H.; Latham, A.; Carlo, M. I.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Association between biomarkers and clinical outcomes of lenvatinib (L) + pembrolizumab (P) in advanced endometrial cancer (EC): Results from KEYNOTE-146/study 111